Therapies

Autoimmune and inflammatory diseases

Artax Biopharma’s products exploit a novel oral therapy that has the potential to treat a broad range of autoimmune and inflammatory diseases. Compounds on Artax pipeline are unique not only for their convenient oral administration but also for their ability to treat both the symptoms and the underlying disease with fewer side effects due to the immunomodulatory profile of the drugs.

Specifically, Artax compound AX-024 has completed Phase Ib studies and has demonstrated proof-of-concept in different animal models for autoimmune diseases.

AX-024

Artax Biopharma’s first product is AX-024 a novel oral therapy that has potential to treat a broad range of autoimmune and inflammatory diseases. It is unique not only for its convenient oral administration, but also for its ability to treat both the symptoms and the underlying disease with fewer side effects due to the immunomodulatory profile of the drug.

AX-024 is currently undergoing clinical studies. It has demonstrated proof-of-concept in animal models of asthma (OVA) and multiple sclerosis (EAE).